Redefining how medicine
is discovered, validated
and made.
Built in Australia. Our Discovery AI platform and our own laboratories carry a therapeutic or diagnostic idea from candidate design to validated, trial ready material, without leaving the country.
One platform. Three connected pillars.
At the centre is Discovery AI, our platform and system. Around it sit the capabilities that share the same engine and laboratories, so the value of every discovery extends across the whole business. This is what it means to be an integrated life sciences company.
Discovery AI
Find the molecules that matter
Our AI platform identifies, validates and designs RNA and DNA therapeutic candidates at a speed and scale impossible by conventional methods.
Explore Syngenis OneManufacturing
Make them here, to clinical grade
From our Bentley WA facility, we synthesise oligonucleotides to GLP standard now and GMP clinical grade from January 2027. Australia's only commercial RNA and DNA manufacturing facility.
Explore ManufacturingPlatform
Research. Clinical. Capital.
The Syngenis Platform brings together our research services, clinical development support through Syngenis Clinical, and the Origin Fund - the ecosystem that takes programs from discovery through to trial and investment.
Explore the PlatformMedicine is moving from chemistry to code.
For a century, medicine was built from chemistry, small molecules that treat the symptoms of disease. RNA and DNA medicines work differently. They read, understand and respond to disease at the molecular level, addressing its cause rather than its effect. This is no longer a promise. RNA interference medicines, antisense oligonucleotides, mRNA vaccines and CRISPR gene editing are already approved and in patients, reaching diseases that were considered untreatable only a decade ago.
The bottleneck is no longer the science. It is the speed of discovery and access to validated, regulated material to move programs forward. Syngenis was built to solve both.
Over 21 RNA and DNA medicines have already received FDA approval, treating patients across rare genetic disease, cardiovascular conditions, and metabolic disorders — including Spinraza (spinal muscular atrophy), Amvuttra (ATTR amyloidosis), Leqvio (high cholesterol), and Onpattro (hereditary transthyretin amyloidosis). This is a proven drug class. The challenge and opportunity now lies in manufacturing capacity, discovery speed, and scale — and that is precisely what Syngenis is built to deliver.
Discovery is too slow, and too fragmented.
Finding the next RNA or DNA breakthrough still takes years of fragmented effort across disconnected tools, teams and suppliers. In Australia there has been no single pathway that carries a discovery from insight to trial ready material on home soil. Every hand off adds delay, cost and exposure of valuable intellectual property. Syngenis closes that gap by bringing AI led discovery, our own laboratories and clinical delivery under one roof.
Partners across research, industry and care.
- Biotechnology companies developing RNA and DNA therapeutics and diagnostics.
- Universities and research institutes needing custom nucleic acids and validated material.
- Clinicians and diagnostics developers seeking point of care tests.
- Consumers, through the Life Care genomics service.
The engine is already running.
Our first AI discovered candidate was designed by Discovery AI and has entered laboratory validation, the first to complete the full discovery to laboratory workflow. Research grade manufacturing is operational and generating revenue today, and we are building GMP grade capability. We work alongside leading Australian and international universities, research institutes and biotechnology companies.
Professor Marvin Caruthers, and why it matters that he stands behind Syngenis.
Almost every synthetic DNA and RNA molecule made anywhere in the world today exists because of one man. In the late 1970s and early 1980s, Professor Marvin Caruthers invented phosphoramidite chemistry, the method that made it possible to build DNA and RNA reliably, repeatedly and at scale. That single invention turned DNA synthesis from a painstaking academic exercise into an industrial capability, and it underpins virtually all modern molecular diagnostics, genomics, gene editing and nucleic acid medicine. When a laboratory anywhere orders an oligonucleotide, it is using his chemistry.
Professor Caruthers did not stop at the science. He co founded Applied Biosystems, which commercialised automated DNA synthesis and sequencing, and Amgen, one of the largest biotechnology companies in the world. His contributions have been recognised with the United States National Medal of Science, the highest scientific honour in the country.
He served as an inaugural Director of Syngenis, shaping its technical direction and long term vision from the very beginning, and in 2025 became the company's Patron. For Syngenis, this is not a name on a page. It means the standards to which our laboratories are built, and the chemistry at the heart of our manufacturing, come from the person who created the field. It anchors the company in the same scientific foundations that created the modern DNA and RNA industry, and it is a signal of the seriousness and pedigree behind everything we do.
Professor Caruthers's solid-phase phosphoramidite chemistry is the foundation upon which every FDA-approved oligonucleotide therapeutic has been synthesised. From Vitravene — the first antisense drug, approved in 1998 — to Spinraza, Amvuttra, and the full catalogue of approved RNA and DNA medicines that followed, his chemistry underpins them all. Having Professor Caruthers as Patron of Syngenis is not a ceremonial appointment. It is a direct connection between the founding chemistry of the field and the company building the next generation of RNA manufacturing and discovery infrastructure.
One engine, working across the whole business.
Bring your program to Syngenis.
Whether you are designing a candidate, ordering custom oligonucleotides, planning a nucleic acid trial or exploring a partnership, we would like to hear from you.
Call 1300 100 111 or send an enquiry.